-- Robert Preidt
TUESDAY, Oct. 15 (HealthDay News) -- People who take
anti-smoking drugs have no higher risk of depression or suicide
than those who use nicotine replacement therapies to help them quit
smoking, according to a new study.
Health officials in the United States and some other countries
have issued safety warnings that the drugs Chantix (varenicline)
and Zyban (bupropion) -- which work by reducing nicotine cravings
and withdrawal symptoms -- may increase the risk of suicide.
"Given the concerns and accompanying safety warnings for these drugs these findings are reassuring for users and prescribers of smoking cessation medicines," study co-lead author Dr. Kyla Thomas, of the University of Bristol, said in a university news release.
In the study, published online Oct. 11 in the
BMJ, researchers analyzed data from more than 119,000
British adults who used different types of products to help them
quit smoking between September 2006 and October 2011. Of those
patients, about 26 percent used Chantix, around 6 percent tried
Zyban and more than two-thirds used nicotine replacement therapies,
such as patches and gum.
There was no clear evidence that people who took Chantix or
Zyban were more likely to experience depression or suicidal
behavior than those who used nicotine replacement therapies, the
The American Cancer Society offers a
guide to quitting smoking.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.